Evaluation of the Effects of Routine Iron Supplementation in Children on Gastrointestinal Iron Losses

Iron Deficiency Anemia Clinical Trial

Official title:

Evaluation of the Effects of Routine Iron Supplementation in Children on Gastrointestinal Iron Losses.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04721964
• Other study ID #: FeLo
• Status: Completed
• Phase: N/A
• Start date: February 25, 2021
• Est. completion date: June 16, 2021

Study information

• Verified date: July 2021
• Source: Swiss Federal Institute of Technology
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Iron deficiency anaemia (IDA) is common among infants and young children in sub-Saharan Africa.Oral iron administration is usually recom-mended as cost effective measure to prevent and treat iron deficiency (ID) and IDA during childhood. In Kenya, national nutrition policies for anaemia prevention recommend a daily dose of 3-6 mg ele-mental iron per kg body weight if a child is diagnosed with anaemia.

Using a novel technology, recent research found increased iron losses during iron supplementation. In an explorative analysis of stool samples collected from Gambian toddlers (Speich et al., 2020), an increase in faecal iron losses during iron supplementation was reported. The present study is aiming to analyse a relationship between routine iron supplementation and increased faecal occult blood losses in 24 Kenyan children with anaemia and iron deficiency in a more structured manner.

Secondary objectives of the study are to measure and monitor iron and inflammatory status during the course of the study and to quantify long-term iron absorption and iron losses during a 12-weeks iron supplementation period, in order to put iron balance into relationship to occurring faecal occult blood losses during such an intervention.

Description:

Infants and young children in sub-Saharan Africa have high rates of iron deficiency anaemia (IDA), which adversely affects their growth and cognitive development. WHO recommends daily administration of 3 mg elemental iron per kg body weight in form of drops or syrup in 6-23 month-old ID or anaemic infants. In settings where anaemia prevalence in this age group is >40%, WHO further recommends daily administration of 10-12.5 mg elemental iron for prevention of ID and anaemia. The Kenyan Ministry of Health adopted the WHO strategy to treat IDA in its "Basic Paediatric Protocols" released in 2016, and specified a dose of 3-6 mg elemental Fe per kg body weight and day.

WHO guidelines for anaemia prevention and control in infants aged 6-23 months are based on a systematic review and meta-analysis of randomized controlled trials investigating the effect of daily iron supplementation on health in infants. The review reported a significantly lower risk of iron-deficiency anaemia in infants when supplemented. However, iron supplements and iron-containing micronutrient powders (MNPs) do not always show efficacy; for example, in a recent large intervention trial in Pakistan, there was no significant effect of 12 months of iron supplementation on haemoglobin status.

Among the many potential factors contributing to the limited success of health and nutrition policies in reducing the prevalence of iron deficiency, increased iron losses during iron supplementation have not been considered. In a recent study in Gambian toddlers, a 3.4-fold increase in iron losses was detected, specifically from 0.22 (0.19;0.29) mg/d to 0.75 (0.55;0.87) mg/d, during a 12-week iron intervention with daily consumption of 12 mg iron as ferrous fumarate in MNPs routinely distributed by the United Nations Children's Fund and the World Food Program. Furthermore, the administered iron dose significantly correlated with faecal haemoglobin concentration in the Gambian toddlers. In a recent iron supplementation pilot study in Kenyan toddlers, the investigators measured a significant increase in faecal haemoglobin concentration during iron supplementation. Increased basal iron losses during iron supplementation could also be detected in 10 Swiss women. Several endoscopy studies have suggested iron supplementation may cause irritation/inflammation of the gut mucosa, potentially leading to gastrointestinal blood losses.

To explore a potential relationship between iron supplementation with common iron supplements and increased faecal occult (small traces of blood, not visible in stool) blood losses, this study will measure haemoglobin and porphyrin content in stool samples collected before and throughout a 91-day iron supplementation intervention. Intervention product will be 6 mg iron / kg body weight as ferric ammonium citrate and ferrous fumarate syrup (Ranbaxy Ranferon-12 Syrup, Ranbaxy Laboratories, Gurgaon, India) administered daily. Faecal occult blood losses will also be compared to absolute iron losses determined by the recently developed dilution of stable iron isotopes methodology. The study population will consist of 24 anaemic 2-years old children in Kwale County of southern coastal Kenya. The hypothesis of the investigators is that iron status will improve, but faecal occult blood losses will increase. The data from this project may provide valuable information towards the development of safer and more effective iron supplementation regimens.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: June 16, 2021
• Est. primary completion date: June 16, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 23 Months to 29 Months

Eligibility

Inclusion Criteria:

• Participation in former Fe_HMO_GOS study (JKUAT/IERC No. 301019) or INSPIRE study (JKUAT/IERC No. JKU/2/4/896B).

• Mildly to moderately anaemic defined as 9.0 g/dL = Hb < 11 g/dL.

• Iron deficiency defined as ZPP >80µmol/mol.

• Willingness of the caregiver to participate in the study.

• Residence in the study area for the period of the study.

• The informed consent form has been read and signed by the participant's caregiver (or has been read out to the participant's caregiver in case of illiteracy)

• Assessment of good health by professional staff at Msambweni District Hospital.

Exclusion Criteria:

• Hb <9 g/L or >11 g/L.

• Zinc ProtoPorphyrin =80 µmol/mol.

• Severe underweight (Z-score weight-for-age =-3).

• Severe wasting (Z-score weight-for-height =-3).

• Antibiotics consumption in the 7 days prior to screening.

• Consumption of iron supplements in the 14 days prior to screening.

• Any severe metabolic, gastrointestinal, kidney or chronic disease such as diabetes, hepatitis, hypertension, cancer or cardiovascular diseases (according to the guardian's statement or medical examination (health booklet)).

• Participants taking part in other studies requiring the drawing of blood or involving medical or physical interventions.

Related Conditions & MeSH terms

• Anemia, Iron-Deficiency
• Gastro Intestinal Bleeding
• Gastrointestinal Hemorrhage
• Iron Deficiency Anemia
• Iron-deficiency

Intervention

Dietary Supplement:
• Ferric ammonium citrate and ferrous fumarate syrup (Ranbaxy Ranferon-12 Syrup, Ranbaxy Laboratories, Gurgaon, India)
Daily supplementation with iron syrup for 13 weeks. The dosage will be calculated based on body weight and adjusted after 4 and 8 weeks of intervention

Locations

Country	Name	City	State
Kenya	Msambweni County Referral Hospital	Mombasa	Kwale

Sponsors (2)

Lead Sponsor	Collaborator
Swiss Federal Institute of Technology	Jomo Kenyatta University of Agriculture and Technology

Country where clinical trial is conducted

Kenya, 

References & Publications (1)

Speich C, Wegmüller R, Brittenham GM, Zeder C, Cercamondi CI, Buhl D, Prentice AM, Zimmermann MB, Moretti D. Measurement of long-term iron absorption and loss during iron supplementation using a stable isotope of iron ((57) Fe). Br J Haematol. 2021 Jan;192(1):179-189. doi: 10.1111/bjh.17039. Epub 2020 Aug 30. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Fecal occult blood concentration	72 h stool samples will be collected from the study participants during 4 collection periods (day 4-7 (baseline), day 32-35, day 60-63, day 95-98). Fecal occult blood concentration in the samples will be estimated from haemoglobin and porphyrin content in stool samples. These measurements will be assessed from stool aliquots, that will be shipped frozen to Mayo Clinic Laboratory (Rochester, USA), using highly specific hemoquant assay.	Day 4-7 (baseline)
Primary	Fecal occult blood concentration	72 h stool samples will be collected from the study participants during 4 collection periods (day 4-7 (baseline), day 32-35, day 60-63, day 95-98). Fecal occult blood concentration in the samples will be estimated from haemoglobin and porphyrin content in stool samples. These measurements will be assessed from stool aliquots, that will be shipped frozen to Mayo Clinic Laboratory (Rochester, USA), using highly specific hemoquant assay.	Day 32-35
Primary	Fecal occult blood concentration	72 h stool samples will be collected from the study participants during 4 collection periods (day 4-7 (baseline), day 32-35, day 60-63, day 95-98). Fecal occult blood concentration in the samples will be estimated from haemoglobin and porphyrin content in stool samples. These measurements will be assessed from stool aliquots, that will be shipped frozen to Mayo Clinic Laboratory (Rochester, USA), using highly specific hemoquant assay.	Day 60-63
Primary	Fecal occult blood concentration	72 h stool samples will be collected from the study participants during 4 collection periods (day 4-7 (baseline), day 32-35, day 60-63, day 95-98). Fecal occult blood concentration in the samples will be estimated from haemoglobin and porphyrin content in stool samples. These measurements will be assessed from stool aliquots, that will be shipped frozen to Mayo Clinic Laboratory (Rochester, USA), using highly specific hemoquant assay.	Day 95-98
Secondary	Iron status: Hemoglobin (g/dl) (Hb)	Venipuncture blood withdrawal (3 mL) will be performed at each hospital visit. Hb concentration will be measured immediately after blood withdrawal using an iCheck Anaemia diagnostic device (BioAnalyt GmbH, Teltow, Germany).	Baseline (day 7)
Secondary	Iron status: Zinc protoporphyrin (µmol/mol) (ZPP)	Venipuncture blood withdrawal (3 mL) will be performed at each hospital visit. ZPP concentration will be measured immediately after blood withdrawal using an iCheck Anaemia diagnostic device (BioAnalyt GmbH, Teltow, Germany).	Baseline (day 7)
Secondary	Iron status: Soluble Transferrin Receptor (mg/L) (sTfR)	Venipuncture blood withdrawal (3 mL) will be performed at each hospital visit. 1 mL full blood samples will then be aliquoted and the remaining blood samples will be centrifuged, all serum aliquoted and stored at -20°C at the study site until all samples will be shipped frozen to ETH Zurich, Switzerland. A serum aliquot of only 100-200 µL will be analysed externally in the VitMin Lab, Willstaett, Germany, using a multiplex ELISA assay developed by Erhardt et al. (Erhardt et al., 2004) for quatification of sTfR concentration.	Baseline (day 7)
Secondary	Iron status: Serum Ferritin (ug/L) (SF)	Venipuncture blood withdrawal (3 mL) will be performed at each hospital visit. 1 mL full blood samples will then be aliquoted and the remaining blood samples will be centrifuged, all serum aliquoted and stored at -20°C at the study site until all samples will be shipped frozen to ETH Zurich, Switzerland. A serum aliquot of only 100-200 µL will be analysed externally in the VitMin Lab, Willstaett, Germany, using a multiplex ELISA assay developed by Erhardt et al. (Erhardt et al., 2004) for quatification of SF concentration.	Baseline (day 7)
Secondary	Iron status: Serum Hepcidin (nM)	Venipuncture blood withdrawal (3 mL) will be performed at each hospital visit.1 mL full blood samples will then be aliquoted and the remaining blood samples will be centrifuged, all serum aliquoted and stored at -20°C at the study site until all samples will be shipped frozen to ETH Zurich, Switzerland, for analysis of serum hepcidin.	Baseline (day 7)
Secondary	Iron status: Hemoglobin (g/dl)	Venipuncture blood withdrawal (3 mL) will be performed at each hospital visit. Hb concentration will be measured immediately after blood withdrawal using an iCheck Anaemia diagnostic device (BioAnalyt GmbH, Teltow, Germany).	Day 35
Secondary	Iron status: Zinc protoporphyrin (µmol/mol)	Venipuncture blood withdrawal (3 mL) will be performed at each hospital visit. ZPP concentration will be measured immediately after blood withdrawal using an iCheck Anaemia diagnostic device (BioAnalyt GmbH, Teltow, Germany).	Day 35
Secondary	Iron status: Soluble Transferrin Receptor (mg/L)	Venipuncture blood withdrawal (3 mL) will be performed at each hospital visit. 1 mL full blood samples will then be aliquoted and the remaining blood samples will be centrifuged, all serum aliquoted and stored at -20°C at the study site until all samples will be shipped frozen to ETH Zurich, Switzerland. A serum aliquot of only 100-200 µL will be analysed externally in the VitMin Lab, Willstaett, Germany, using a multiplex ELISA assay developed by Erhardt et al. (Erhardt et al., 2004) for quatification of sTfR concentration.	Day 35
Secondary	Iron status: Serum Ferritin (ug/L)	Venipuncture blood withdrawal (3 mL) will be performed at each hospital visit. 1 mL full blood samples will then be aliquoted and the remaining blood samples will be centrifuged, all serum aliquoted and stored at -20°C at the study site until all samples will be shipped frozen to ETH Zurich, Switzerland. A serum aliquot of only 100-200 µL will be analysed externally in the VitMin Lab, Willstaett, Germany, using a multiplex ELISA assay developed by Erhardt et al. (Erhardt et al., 2004) for quatification of SF concentration.	Day 35
Secondary	Iron status: Serum Hepcidin (nM)	Venipuncture blood withdrawal (3 mL) will be performed at each hospital visit.1 mL full blood samples will then be aliquoted and the remaining blood samples will be centrifuged, all serum aliquoted and stored at -20°C at the study site until all samples will be shipped frozen to ETH Zurich, Switzerland, for analysis of serum hepcidin.	Day 35
Secondary	Iron status: Hemoglobin (g/dl)	Venipuncture blood withdrawal (3 mL) will be performed at each hospital visit. Hb concentration will be measured immediately after blood withdrawal using an iCheck Anaemia diagnostic device (BioAnalyt GmbH, Teltow, Germany).	Day 63
Secondary	Iron status: Zinc protoporphyrin (µmol/mol)	Venipuncture blood withdrawal (3 mL) will be performed at each hospital visit. ZPP concentration will be measured immediately after blood withdrawal using an iCheck Anaemia diagnostic device (BioAnalyt GmbH, Teltow, Germany).	Day 63
Secondary	Iron status: Soluble Transferrin Receptor (mg/L)	Venipuncture blood withdrawal (3 mL) will be performed at each hospital visit. 1 mL full blood samples will then be aliquoted and the remaining blood samples will be centrifuged, all serum aliquoted and stored at -20°C at the study site until all samples will be shipped frozen to ETH Zurich, Switzerland. A serum aliquot of only 100-200 µL will be analysed externally in the VitMin Lab, Willstaett, Germany, using a multiplex ELISA assay developed by Erhardt et al. (Erhardt et al., 2004) for quatification of sTfR concentration.	Day 63
Secondary	Iron status: Serum Ferritin (ug/L)	Venipuncture blood withdrawal (3 mL) will be performed at each hospital visit. 1 mL full blood samples will then be aliquoted and the remaining blood samples will be centrifuged, all serum aliquoted and stored at -20°C at the study site until all samples will be shipped frozen to ETH Zurich, Switzerland. A serum aliquot of only 100-200 µL will be analysed externally in the VitMin Lab, Willstaett, Germany, using a multiplex ELISA assay developed by Erhardt et al. (Erhardt et al., 2004) for quatification of SF concentration.	Day 63
Secondary	Iron status: Serum Hepcidin (nM)	Venipuncture blood withdrawal (3 mL) will be performed at each hospital visit.1 mL full blood samples will then be aliquoted and the remaining blood samples will be centrifuged, all serum aliquoted and stored at -20°C at the study site until all samples will be shipped frozen to ETH Zurich, Switzerland, for analysis of serum hepcidin.	Day 63
Secondary	Iron status: Hemoglobin (g/dl)	Venipuncture blood withdrawal (3 mL) will be performed at each hospital visit. Hb concentration will be measured immediately after blood withdrawal using an iCheck Anaemia diagnostic device (BioAnalyt GmbH, Teltow, Germany).	Day 98
Secondary	Iron status: Zinc protoporphyrin (µmol/mol)	Venipuncture blood withdrawal (3 mL) will be performed at each hospital visit. ZPP concentration will be measured immediately after blood withdrawal using an iCheck Anaemia diagnostic device (BioAnalyt GmbH, Teltow, Germany).	Day 98
Secondary	Iron status: Soluble Transferrin Receptor (mg/L)	Venipuncture blood withdrawal (3 mL) will be performed at each hospital visit. 1 mL full blood samples will then be aliquoted and the remaining blood samples will be centrifuged, all serum aliquoted and stored at -20°C at the study site until all samples will be shipped frozen to ETH Zurich, Switzerland. A serum aliquot of only 100-200 µL will be analysed externally in the VitMin Lab, Willstaett, Germany, using a multiplex ELISA assay developed by Erhardt et al. (Erhardt et al., 2004) for quatification of sTfR concentration.	Day 98
Secondary	Iron status: Serum Ferritin (ug/L)	Venipuncture blood withdrawal (3 mL) will be performed at each hospital visit. 1 mL full blood samples will then be aliquoted and the remaining blood samples will be centrifuged, all serum aliquoted and stored at -20°C at the study site until all samples will be shipped frozen to ETH Zurich, Switzerland. A serum aliquot of only 100-200 µL will be analysed externally in the VitMin Lab, Willstaett, Germany, using a multiplex ELISA assay developed by Erhardt et al. (Erhardt et al., 2004) for quatification of SF concentration.	Day 98
Secondary	Iron status: Serum Hepcidin (nM)	Venipuncture blood withdrawal (3 mL) will be performed at each hospital visit.1 mL full blood samples will then be aliquoted and the remaining blood samples will be centrifuged, all serum aliquoted and stored at -20°C at the study site until all samples will be shipped frozen to ETH Zurich, Switzerland, for analysis of serum hepcidin.	Day 98
Secondary	Inflammation status: alpha Glycoprotein (g/L)	Venipuncture blood withdrawal (3 mL) will be performed at each hospital visit. After aliquotting 1 mL full blood samples, the remaining blood samples will be centrifuged, all serum aliquoted and stored at -20°C at the study site until all samples will be shipped frozen to ETH Zurich, Switzerland. A serum aliquot of only 100-200 µL will be analysed externally in the VitMin Lab, Willstaett, Germany, using a multiplex ELISA assay developed by Erhardt et al. (Erhardt et al., 2004) for quantification of AGP.	Baseline (day 7)
Secondary	Inflammation status: C-reactive protein (mg/L)	Venipuncture blood withdrawal (3 mL) will be performed at each hospital visit. After aliquotting 1 mL full blood samples, the remaining blood samples will be centrifuged, all serum aliquoted and stored at -20°C at the study site until all samples will be shipped frozen to ETH Zurich, Switzerland. A serum aliquot of only 100-200 µL will be analysed externally in the VitMin Lab, Willstaett, Germany, using a multiplex ELISA assay developed by Erhardt et al. (Erhardt et al., 2004) for quantification of CRP.	Baseline (day 7)
Secondary	Inflammation status: Fatty Acids Binding Protein (ng/ml)	Venipuncture blood withdrawal (3 mL) will be performed at each hospital visit. After aliquotting 1 mL full blood samples, the remaining blood samples will be centrifuged, all serum aliquoted and stored at -20°C at the study site until all samples will be shipped frozen to ETH Zurich, Switzerland.; I-FABP concentrations will be analysed after completion of the study at the ETH laboratory, using commercially available ELISA kits.	Baseline (day 7)
Secondary	Inflammation status: C-reactive protein (mg/L)	Venipuncture blood withdrawal (3 mL) will be performed at each hospital visit. After aliquotting 1 mL full blood samples, the remaining blood samples will be centrifuged, all serum aliquoted and stored at -20°C at the study site until all samples will be shipped frozen to ETH Zurich, Switzerland. A serum aliquot of only 100-200 µL will be analysed externally in the VitMin Lab, Willstaett, Germany, using a multiplex ELISA assay developed by Erhardt et al. (Erhardt et al., 2004) for quantification of CRP.	Day 35
Secondary	Inflammation status: alpha Glycoprotein (g/L)	Venipuncture blood withdrawal (3 mL) will be performed at each hospital visit. After aliquotting 1 mL full blood samples, the remaining blood samples will be centrifuged, all serum aliquoted and stored at -20°C at the study site until all samples will be shipped frozen to ETH Zurich, Switzerland. A serum aliquot of only 100-200 µL will be analysed externally in the VitMin Lab, Willstaett, Germany, using a multiplex ELISA assay developed by Erhardt et al. (Erhardt et al., 2004) for quantification of AGP.	Day 35
Secondary	Inflammation status: Fatty Acids Binding Protein (ng/ml)	Venipuncture blood withdrawal (3 mL) will be performed at each hospital visit. After aliquotting 1 mL full blood samples, the remaining blood samples will be centrifuged, all serum aliquoted and stored at -20°C at the study site until all samples will be shipped frozen to ETH Zurich, Switzerland.; I-FABP concentrations will be analysed after completion of the study at the ETH laboratory, using commercially available ELISA kits.	Day 35
Secondary	Inflammation status: C-reactive protein (mg/L)	Venipuncture blood withdrawal (3 mL) will be performed at each hospital visit. After aliquotting 1 mL full blood samples, the remaining blood samples will be centrifuged, all serum aliquoted and stored at -20°C at the study site until all samples will be shipped frozen to ETH Zurich, Switzerland. A serum aliquot of only 100-200 µL will be analysed externally in the VitMin Lab, Willstaett, Germany, using a multiplex ELISA assay developed by Erhardt et al. (Erhardt et al., 2004) for quantification of CRP.	Day 63
Secondary	Inflammation status: alpha Glycoprotein (g/L)	Venipuncture blood withdrawal (3 mL) will be performed at each hospital visit. After aliquotting 1 mL full blood samples, the remaining blood samples will be centrifuged, all serum aliquoted and stored at -20°C at the study site until all samples will be shipped frozen to ETH Zurich, Switzerland. A serum aliquot of only 100-200 µL will be analysed externally in the VitMin Lab, Willstaett, Germany, using a multiplex ELISA assay developed by Erhardt et al. (Erhardt et al., 2004) for quantification of AGP.	Day 63
Secondary	Inflammation status: Fatty Acids Binding Protein (ng/ml)	Venipuncture blood withdrawal (3 mL) will be performed at each hospital visit. After aliquotting 1 mL full blood samples, the remaining blood samples will be centrifuged, all serum aliquoted and stored at -20°C at the study site until all samples will be shipped frozen to ETH Zurich, Switzerland.; I-FABP concentrations will be analysed after completion of the study at the ETH laboratory, using commercially available ELISA kits.	Day 63
Secondary	Inflammation status: C-reactive protein (mg/L)	Venipuncture blood withdrawal (3 mL) will be performed at each hospital visit. After aliquotting 1 mL full blood samples, the remaining blood samples will be centrifuged, all serum aliquoted and stored at -20°C at the study site until all samples will be shipped frozen to ETH Zurich, Switzerland. A serum aliquot of only 100-200 µL will be analysed externally in the VitMin Lab, Willstaett, Germany, using a multiplex ELISA assay developed by Erhardt et al. (Erhardt et al., 2004) for quantification of CRP. .	Day 98
Secondary	Inflammation status: alpha Glycoprotein (g/L)	Venipuncture blood withdrawal (3 mL) will be performed at each hospital visit. After aliquotting 1 mL full blood samples, the remaining blood samples will be centrifuged, all serum aliquoted and stored at -20°C at the study site until all samples will be shipped frozen to ETH Zurich, Switzerland. A serum aliquot of only 100-200 µL will be analysed externally in the VitMin Lab, Willstaett, Germany, using a multiplex ELISA assay developed by Erhardt et al. (Erhardt et al., 2004) for quantification of AGP.	Day 98
Secondary	Inflammation status: Fatty Acids Binding Protein (ng/ml)	Venipuncture blood withdrawal (3 mL) will be performed at each hospital visit. After aliquotting 1 mL full blood samples, the remaining blood samples will be centrifuged, all serum aliquoted and stored at -20°C at the study site until all samples will be shipped frozen to ETH Zurich, Switzerland.; I-FABP concentrations will be analysed after completion of the study at the ETH laboratory, using commercially available ELISA kits.	Day 98
Secondary	Red Blood Cells isotopic composition	Venipuncture blood withdrawal (3 mL) will be performed at each hospital visit. 1 mL full blood samples will be aliquoted and stored at -20°C at the study site until all samples will be shipped frozen to ETH Zurich, Switzerland. For iron isotopic composition each blood sample will be analysed in duplicate under chemical blank monitoring. Whole blood samples will be mineralised using an HNO3 and microwave digestion. This is followed by a separation of the sample matrix by anion-exchange chromatography and a subsequent precipitation step with ammonium hydroxide. The isotopic analyses will be performed by inductively coupled plasma mass spectrometry (ICPMS) using a high resolution double focusing mass spectrometer equipped with a multi-collector system for simultaneous ion beam detection.	Baseline (day 7)
Secondary	Red Blood Cells isotopic composition	Venipuncture blood withdrawal (3 mL) will be performed at each hospital visit. 1 mL full blood samples will be aliquoted and stored at -20°C at the study site until all samples will be shipped frozen to ETH Zurich, Switzerland. For iron isotopic composition each blood sample will be analysed in duplicate under chemical blank monitoring. Whole blood samples will be mineralised using an HNO3 and microwave digestion. This is followed by a separation of the sample matrix by anion-exchange chromatography and a subsequent precipitation step with ammonium hydroxide. The isotopic analyses will be performed by inductively coupled plasma mass spectrometry (ICPMS) using a high resolution double focusing mass spectrometer equipped with a multi-collector system for simultaneous ion beam detection.	Day 35
Secondary	Red Blood Cells isotopic composition	Venipuncture blood withdrawal (3 mL) will be performed at each hospital visit. 1 mL full blood samples will be aliquoted and stored at -20°C at the study site until all samples will be shipped frozen to ETH Zurich, Switzerland. For iron isotopic composition each blood sample will be analysed in duplicate under chemical blank monitoring. Whole blood samples will be mineralised using an HNO3 and microwave digestion. This is followed by a separation of the sample matrix by anion-exchange chromatography and a subsequent precipitation step with ammonium hydroxide. The isotopic analyses will be performed by inductively coupled plasma mass spectrometry (ICPMS) using a high resolution double focusing mass spectrometer equipped with a multi-collector system for simultaneous ion beam detection.	Day 63
Secondary	Red Blood Cells isotopic composition	Venipuncture blood withdrawal (3 mL) will be performed at each hospital visit. 1 mL full blood samples will be aliquoted and stored at -20°C at the study site until all samples will be shipped frozen to ETH Zurich, Switzerland. For iron isotopic composition each blood sample will be analysed in duplicate under chemical blank monitoring. Whole blood samples will be mineralised using an HNO3 and microwave digestion. This is followed by a separation of the sample matrix by anion-exchange chromatography and a subsequent precipitation step with ammonium hydroxide. The isotopic analyses will be performed by inductively coupled plasma mass spectrometry (ICPMS) using a high resolution double focusing mass spectrometer equipped with a multi-collector system for simultaneous ion beam detection.	Day 98
Secondary	Fecal calprotectin concentration	72 h stool samples will be collected from the study participants during 4 collection periods (day 4-7 (baseline), day 32-35, day 60-63, day 95-98). Stool aliquots will be shipped frozen to ETH Zurich, Switzerland, for determination of calprotectin content using commercially available calprotectin kits.	Day 4-7 (baseline)
Secondary	Fecal calprotectin concentration	72 h stool samples will be collected from the study participants during 4 collection periods (day 4-7 (baseline), day 32-35, day 60-63, day 95-98). Stool aliquots will be shipped frozen to ETH Zurich, Switzerland, for determination of calprotectin content using commercially available calprotectin kits.	Day 32-35
Secondary	Fecal calprotectin concentration	72 h stool samples will be collected from the study participants during 4 collection periods (day 4-7 (baseline), day 32-35, day 60-63, day 95-98). Stool aliquots will be shipped frozen to ETH Zurich, Switzerland, for determination of calprotectin content using commercially available calprotectin kits.	Day 60-63
Secondary	Fecal calprotectin concentration	72 h stool samples will be collected from the study participants during 4 collection periods (day 4-7 (baseline), day 32-35, day 60-63, day 95-98). Stool aliquots will be shipped frozen to ETH Zurich, Switzerland, for determination of calprotectin content using commercially available calprotectin kits.	Day 95-98